KROS
Keros Therapeutics, Inc.Company Information
- Company Name
- Keros Therapeutics, Inc.
- CIK
- CIK0001664710
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KROS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KROS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-17
- Last sale
- 2026-08-18
- Shares purchased (TTM)
- 7,000
- Shares sold (TTM)
- 10,215,220
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 18,397,058
- Shares outstanding
- 19,800,322
- Ownership
- 92.91%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- 9.10%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 258 | 281 | 287 | 693 | 690 | 721 | 560 | 531 | 406 | 442 | 331 | 288 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 4 | 3 | 16 | 17 | 3 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 7 | 7 | 22 | 22 | 27 | 22 | 26 | 21 | 27 | 20 | 16 | 17 | ||||||
| Income Taxes Receivable | 2 | 2 | 2 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 267 | 291 | 315 | 719 | 733 | 760 | 589 | 552 | 433 | 463 | 347 | 304 | ||||||
| Operating Lease Right Of Use Asset | 16 | 16 | 17 | 17 | 18 | 19 | 19 | 20 | 15 | 15 | 15 | 16 | ||||||
| Property Plant And Equipment Net | 4 | 4 | 4 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 288 | 312 | 338 | 743 | 757 | 785 | 616 | 579 | 455 | 486 | 370 | 326 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 2 | 2 | 5 | 7 | 5 | 5 | 7 | 5 | 5 | 4 | ||||||
| Operating Lease Liability Current | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 8 | 9 | 16 | 15 | 20 | 17 | 21 | 22 | 14 | 13 | 18 | 12 | ||||||
| Contract With Customer Liability Current | - | - | - | 0 | 1 | 3 | - | - | - | - | - | - | ||||||
| Accrued Income Taxes Current | - | - | - | 4 | 6 | 10 | - | - | - | - | - | - | ||||||
| Liabilities Current | 12 | 13 | 20 | 24 | 35 | 39 | 27 | 29 | 21 | 19 | 24 | 17 | ||||||
| Operating Lease Liability Noncurrent | 13 | 14 | 14 | 15 | 16 | 16 | 17 | 17 | 13 | 13 | 13 | 14 | ||||||
| Liabilities | 25 | 27 | 35 | 39 | 50 | 56 | 44 | 46 | 34 | 32 | 38 | 30 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Value | -385 | -385 | -385 | - | - | - | 0 | - | - | - | - | - | ||||||
| Additional Paid In Capital | 1,181 | 1,176 | 1,169 | 1,162 | 1,158 | 1,149 | 1,140 | 1,056 | 891 | 878 | 714 | 637 | ||||||
| Retained Earnings Accumulated Deficit | -534 | -505 | -482 | -458 | -451 | -420 | -569 | -523 | -470 | -425 | -381 | -341 | ||||||
| Stockholders Equity | 262 | 286 | 303 | 704 | 707 | 729 | 572 | 533 | 421 | 454 | 332 | 296 | ||||||
| Liabilities And Stockholders Equity | 288 | 312 | 338 | 743 | 757 | 785 | 616 | 579 | 455 | 486 | 370 | 326 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 39 | 36 | 36 | 32 | 30 | ||||||
| Shares Outstanding | 20 | 20 | 20 | 41 | 41 | 41 | 41 | 39 | 36 | 36 | 32 | 30 | ||||||
| Treasury Stock Common Shares | 21 | 21 | 21 | - | - | - | 0 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKeros Therapeutics, Inc. (KROS) — SEC Financial Statements & Analysis
Keros Therapeutics, Inc. (KROS) is a pharmaceutical preparations company. Keros Therapeutics, Inc. trades on Nasdaq as: KROS. Keros Therapeutics, Inc. (KROS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Keros Therapeutics, Inc. carries a market cap of $211.86M, a P/E ratio of -2.55x, a P/B ratio of 0.81x, a P/S ratio of 14.11x, an enterprise value of $-47.19M, and an EV/EBITDA multiple of 0.47x. On profitability, it posts an operating margin of -675.82%, a net margin of -553.88%, a Return on Equity (ROE) of -17.16%, a Return on Assets (ROA) of -15.92%, and a Return on Invested Capital (ROIC) of -871.26%. Per share, it reports EPS of $-4.20, diluted EPS of $-4.20, free cash flow per share of $-2.45, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -93.55% year-over-year, net income growth of -542.97% year-over-year, and EPS growth of -1008.59% year-over-year. On the balance sheet, it maintains a current ratio of 21.96x, a quick ratio of 21.38x, working capital of $254.73M, a debt-to-equity ratio of 0.10x, a debt ratio of 0.09, free cash flow of $-48.49M (TTM), and net debt of $-259.06M. Figures sourced from SEC EDGAR.
- Market Cap
- $211.86M
- P/E TTM
- -2.55x
- EPS TTM
- $-4.20
- P/B TTM
- 0.81x
- ROE TTM
- -17.16%
- ROA TTM
- -15.92%
- Debt To Equity
- 0.10x
- Free Cash Flow TTM
- $-48.49M
- Net Revenue TTM Growth 1Y
- -93.55%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Keros Therapeutics, Inc. in?
Keros Therapeutics, Inc. (KROS) operates in the Pharmaceutical Preparations industry.
What exchange does KROS trade on?
Keros Therapeutics, Inc. (KROS) trades on the Nasdaq.
When was Keros Therapeutics, Inc. (KROS)'s most recent SEC filing?
Keros Therapeutics, Inc. (KROS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is KROS's market cap?
Keros Therapeutics, Inc. (KROS) has a market capitalization of $211.86M as of 2026-06-30.
What is KROS's EPS (earnings per share)?
Keros Therapeutics, Inc. (KROS)'s trailing twelve month EPS is $-4.20 as of 2026-06-30.
What is KROS's ROE (return on equity)?
Keros Therapeutics, Inc. (KROS)'s trailing twelve month Return on Equity (ROE) is -17.16% as of 2026-06-30.
What is KROS's ROA (return on assets)?
Keros Therapeutics, Inc. (KROS)'s trailing twelve month Return on Assets (ROA) is -15.92% as of 2026-06-30.
What is KROS's ROIC (return on invested capital)?
Keros Therapeutics, Inc. (KROS)'s trailing twelve month Return on Invested Capital (ROIC) is -871.26% as of 2026-06-30.
What is KROS's EV/EBITDA?
Keros Therapeutics, Inc. (KROS)'s trailing twelve month EV/EBITDA is 0.47x as of 2026-06-30.